Marina Biotech (MRNA) Posts Wider than Expected Q1 Loss

Marina Biotech, Inc. (Nasdaq: MRNA) reported Q1 loss of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $214 million versus the consensus estimate of $150 thousand.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA advisory panel votes 9-0 in favor of Moderna's mRNA flu vaccine
• Jabil (JBL) Tops Q3 EPS by 8c, Offers Guidance
• Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine